Mesenchymal Stem/Stromal Cell Extracellular Vesicles: From Active Principle to Next Generation Drug Delivery

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue focused on extracellular vesicles (EVs) derived from mesenchymal stem/stromal cells (MSCs) and their potential use in the clinic. MSCs are the most studied source of therapeutic EVs, which are increasingly emerging as a new promising cell-free therapy. EVs have unique features which make them candidates as suitable alternatives to cell therapy; these include their safety, versatile biological actions and targeting ability. Moreover, their natural role as vehicles between cells makes them the ideal delivery system, which can replace current technologies and avoid their limitations.

This Special Issue aims to provide an overview of the knowledge about the potentiality of MSC-EVs in therapeutic applications, focusing on their effect as active principle and their modification as drug vehicles. This Special Issue will summarize the latest discoveries on the application of EVs which can include their use in clinic and aspects from production to therapeutic effect, with particular interest in their use as drug carriers.

In this Special Issue, original research articles and reviews are welcome. Research areas on MSC-EVs may include (but are not limited to) the following: therapeutic effect in pathological preclinical models, methods and application as drug delivery systems, as well as their production and challenges for their clinical use.

I look forward to receiving your contributions.

Dr. Margherita Pomatto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.